DK1001792T3 - Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser - Google Patents

Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser

Info

Publication number
DK1001792T3
DK1001792T3 DK98937862T DK98937862T DK1001792T3 DK 1001792 T3 DK1001792 T3 DK 1001792T3 DK 98937862 T DK98937862 T DK 98937862T DK 98937862 T DK98937862 T DK 98937862T DK 1001792 T3 DK1001792 T3 DK 1001792T3
Authority
DK
Denmark
Prior art keywords
physiologically acceptable
complexes
salts
vanadium compounds
acceptable vanadium
Prior art date
Application number
DK98937862T
Other languages
Danish (da)
English (en)
Inventor
Conradus Ghosal Gho
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Application granted granted Critical
Publication of DK1001792T3 publication Critical patent/DK1001792T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98937862T 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser DK1001792T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
PCT/NL1998/000431 WO1999006056A1 (fr) 1997-07-29 1998-07-29 Utilisation de composes, de sels et de complexes de vanadium acceptables sur le plan physiologique

Publications (1)

Publication Number Publication Date
DK1001792T3 true DK1001792T3 (da) 2004-01-19

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937862T DK1001792T3 (da) 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser

Country Status (22)

Country Link
US (2) US6579540B1 (fr)
EP (1) EP1001792B1 (fr)
JP (1) JP2001511454A (fr)
CN (1) CN1104244C (fr)
AT (1) ATE253373T1 (fr)
AU (1) AU738701B2 (fr)
BR (1) BR9811298A (fr)
CA (1) CA2298645C (fr)
CZ (1) CZ299716B6 (fr)
DE (1) DE69819514T2 (fr)
DK (1) DK1001792T3 (fr)
EA (1) EA002574B1 (fr)
ES (1) ES2207851T3 (fr)
ID (1) ID24870A (fr)
IL (2) IL134259A0 (fr)
NL (1) NL1006681C2 (fr)
NO (1) NO20000446L (fr)
NZ (1) NZ502613A (fr)
PL (1) PL338415A1 (fr)
PT (1) PT1001792E (fr)
TR (1) TR200000349T2 (fr)
WO (1) WO1999006056A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
AU1898700A (en) * 1999-12-20 2001-07-03 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and NA+/H+ exchange inhibitor
WO2003041703A2 (fr) * 2001-11-16 2003-05-22 Gho Holding B.V. Methode de traitement des brulures
EP2275560A3 (fr) 2007-01-31 2012-01-25 BASF Plant Science GmbH Plantes transgénique, comprenant comme transgène un membre de la famille des REMORIN ou une séquence consensus de cette famille, ayant des charactéristiques de rendement améliorées et procédé de fabrication de celles-ci
MX2009011716A (es) 2007-05-03 2009-12-11 Basf Plant Science Gmbh Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas.
US8697947B2 (en) 2007-07-20 2014-04-15 Basf Plant Science Gmbh Plants having increased yield-related traits and a method for making the same
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
BRPI0818482A2 (pt) 2007-10-29 2014-10-07 Basf Plant Science Gmbh Método para intensificar as características relacionadas ao redimento, constructo, uso de um constructo, planta , parte de planta ou célula de planta, método para a produção de uma planta transgênica, planta transgênica, partes colhíves de uma planta, produtos, e, uso de um ácido nucleico
AU2009243552A1 (en) 2008-05-05 2009-11-12 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
BR112012017535A2 (pt) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University uso de compostos de vanádio para cicatrização de osso
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
JP5992917B2 (ja) 2010-12-10 2016-09-14 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー インスリン疑似剤コンポジットで被覆される埋め込み型デバイスおよびその方法
BR112013022907A2 (pt) 2011-03-07 2016-09-13 Cfm Pharma Holding Bv composição farmacêutica
US9931348B2 (en) * 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
ID24870A (id) 2000-08-31
EA200000176A1 (ru) 2000-10-30
AU738701B2 (en) 2001-09-27
EA002574B1 (ru) 2002-06-27
NL1006681C2 (nl) 1999-02-08
DE69819514T2 (de) 2004-09-23
TR200000349T2 (tr) 2000-09-21
PL338415A1 (en) 2000-11-06
CZ299716B6 (cs) 2008-10-29
ES2207851T3 (es) 2004-06-01
NO20000446L (no) 2000-03-24
NZ502613A (en) 2001-08-31
EP1001792B1 (fr) 2003-11-05
CN1270525A (zh) 2000-10-18
BR9811298A (pt) 2000-08-29
ATE253373T1 (de) 2003-11-15
US6579540B1 (en) 2003-06-17
DE69819514D1 (de) 2003-12-11
IL134259A0 (en) 2001-04-30
AU8650598A (en) 1999-02-22
JP2001511454A (ja) 2001-08-14
IL134259A (en) 2010-02-17
PT1001792E (pt) 2004-03-31
EP1001792A1 (fr) 2000-05-24
CZ2000326A3 (cs) 2000-07-12
WO1999006056A1 (fr) 1999-02-11
CA2298645C (fr) 2004-05-18
US20030211170A1 (en) 2003-11-13
CN1104244C (zh) 2003-04-02
CA2298645A1 (fr) 1999-02-11
NO20000446D0 (no) 2000-01-28

Similar Documents

Publication Publication Date Title
DK1001792T3 (da) Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
BR0109703A (pt) Derivados de piperazina
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
WO1995031985A3 (fr) Compositions pharmaceutiques contenant un antagoniste des opiaces et des sels de calcium, et leur utilisation dans le traitement de pathologies a mediation endorphinique
ATE252081T1 (de) Neue hiv-protease-inhibitoren
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ES2128043T3 (es) Uso de bis(amidinobencimidazoles) en la preparacion de un medicamento para inhibir la integrasa retroviral.
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
EP0970700A3 (fr) Médicaments contenant du gallium pour activer la cicatrisation des plaies et la réparation des tissus
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
SE9802209D0 (sv) Novel compounds
CA2385755A1 (fr) Prevention du cancer colorectal
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
WO2001016096A3 (fr) Utilisation de bisulfonamides pour preparer des medicaments s'utilisant pour assurer la prophylaxie ou le traitement de l'hyperlipidemie
BR0115911A (pt) Uso de pirazolo[4,3-d]pirimidinas
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων